Parkhurst NuVision, a leading ophthalmic clinic and Glaukos have reached a significant milestone with the U.S. Food and Drug Administration (FDA) approval of its New Drug Application (NDA) for iDose® TR (travoprost intracameral implant) 75 mcg. This pioneering prostaglandin analog…
FDA Approves Groundbreaking iDose® TR for Glaucoma Treatment Following Successful Clinical Trials Conducted by Parkhurst NuVision and Glaukos
This post was originally published on this site